Genomic Evolution of Breast Cancer Metastasis and Relapse
暂无分享,去创建一个
P. Lønning | M. Stratton | P. Campbell | C. Sotiriou | C. Desmedt | A. Sieuwerts | D. Wedge | L. Yates | David Jones | C. Latimer | L. Mudie | K. Raine | A. Tutt | A. Richardson | M. Gerstung | G. Gundem | P. Van Loo | I. Martincorena | L. Alexandrov | S. Knappskog | E. Sawyer | Santiago Gonzalez | A. Lynch | S. Bhosle | H. K. Haugland | P. Lilleng | J. Martens | J. R. Farmery | Elli Pappaemmanuil | P. Gazinska | Calli Latimer
[1] Ian Krop,et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Lajos Pusztai,et al. Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations , 2017, Nature Communications.
[3] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[4] Jessica M. Rusert,et al. Extrachromosomal oncogene amplification drives tumor evolution and genetic heterogeneity , 2017, Nature.
[5] K. White,et al. Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing , 2016, Genome Biology.
[6] Stephen Fox,et al. The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program “CASCADE” , 2016, PLoS medicine.
[7] Christopher A. Miller,et al. Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases , 2016, PLoS medicine.
[8] Christopher A. Miller,et al. Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation , 2016, Nature Communications.
[9] G. Hortobagyi,et al. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. , 2016, JAMA oncology.
[10] R. Bast,et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Christophe Badie,et al. Mutational signatures of ionizing radiation in second malignancies , 2016, Nature Communications.
[12] Christopher A. Miller,et al. Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers , 2016, Nature Communications.
[13] Funda Meric-Bernstam,et al. Punctuated Copy Number Evolution and Clonal Stasis in Triple-Negative Breast Cancer , 2016, Nature Genetics.
[14] T. Graeber,et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.
[15] G. Getz,et al. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis , 2016, Nature Genetics.
[16] David C. Jones,et al. Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.
[17] R. Yelensky,et al. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence , 2016, Science Translational Medicine.
[18] S. Loi,et al. Precision medicine for metastatic breast cancer—limitations and solutions , 2015, Nature Reviews Clinical Oncology.
[19] Steven J. M. Jones,et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.
[20] Robert T. Jones,et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. , 2015, Cancer discovery.
[21] Joshy George,et al. Whole–genome characterization of chemoresistant ovarian cancer , 2015, Nature.
[22] Andrew Menzies,et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing , 2015, Nature Medicine.
[23] M. Stratton,et al. High burden and pervasive positive selection of somatic mutations in normal human skin , 2015, Science.
[24] Anne Vincent-Salomon,et al. Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification , 2015, Genome Biology.
[25] Shenmin Zhang,et al. Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma , 2015, Journal of Experimental & Clinical Cancer Research.
[26] Obi L. Griffith,et al. Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor , 2014, Nature.
[27] M. Berger,et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] N. Navin,et al. Clonal Evolution in Breast Cancer Revealed by Single Nucleus Genome Sequencing , 2014, Nature.
[29] R. Yelensky,et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. , 2014, Cancer discovery.
[30] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[31] Javed Siddiqui,et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.
[32] David Chen,et al. ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.
[33] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[34] Paul T. Spellman,et al. Methods and challenges in timing chromosomal abnormalities within cancer samples , 2013, Bioinform..
[35] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[36] R. Gray,et al. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy , 2013, Cancer.
[37] M. Stratton,et al. Deciphering Signatures of Mutational Processes Operative in Human Cancer , 2013, Cell reports.
[38] Trevor J Pugh,et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation , 2013, Nucleic acids research.
[39] 片桐 敦子. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma , 2013 .
[40] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[41] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[42] Irmtraud M. Meyer,et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers , 2012, Nature.
[43] A. Sivachenko,et al. Sequence analysis of mutations and translocations across breast cancer subtypes , 2012, Nature.
[44] A. Børresen-Dale,et al. The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.
[45] A. Børresen-Dale,et al. The Life History of 21 Breast Cancers , 2012, Cell.
[46] Joshua F. McMichael,et al. Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.
[47] H. Katagiri,et al. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma , 2012, Modern Pathology.
[48] N. Carter,et al. Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development , 2011, Cell.
[49] C. Perou,et al. Allele-specific copy number analysis of tumors , 2010, Proceedings of the National Academy of Sciences.
[50] Joshua F. McMichael,et al. Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft , 2010, Nature.
[51] A. Ashworth,et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. , 2010, Cancer research.
[52] Derek Y. Chiang,et al. The landscape of somatic copy-number alteration across human cancers , 2010, Nature.
[53] Ryan D. Morin,et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.
[54] P. Donnelly,et al. A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies , 2009, PLoS genetics.
[55] C. Klein,et al. Parallel progression of primary tumours and metastases , 2009, Nature Reviews Cancer.
[56] M. Olivier,et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database , 2007, Human mutation.
[57] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[58] J. Foekens,et al. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] T. Aas,et al. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.